Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.

Expanding Access to Lifesaving Therapies in LATAM

In the Latin America (LATAM) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 8 commercialized biosimilars. Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the LATAM region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.

Focused on Making a Meaningful Difference in Brazil

In Brazil, Biocon Biologics operates from its office in São Paulo. Through its self-led and partner-led commercial models, the company is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease for the benefit of patients and improving healthcare outcomes in Brazil. Biocon Biologics has five commercialized products in Brazil —Insugen, a biosimilar to recombinant human insulin (Rh-Insulin), used for managing diabetes, Zedora, a biosimilar to Trastuzumab, used in the treatment of HER2-positive breast cancer, Abevmy and Simbeva, both biosimilars to Bevacizumab, used for treating various cancers, including colorectal, lung, and kidney cancers, Fulphila and Pegneucyte, both biosimilars to Pegfilgrastim, which help reduce the risk of infection in patients undergoing chemotherapy, Hulio, a biosimilar to Adalimumab, used in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, and Nepexto, a biosimilar to Etanercept, used for treating autoimmune conditions like rheumatoid arthritis.

Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in Brazil. As a trusted and reliable company, Biocon Biologics is poised to grow and consolidate its leadership in biosimilars in Brazil, making a meaningful impact on patients’ lives.

In Brazil, Trastuzumab is commercialized by our partner Libbs, and Bevacizumab and Pegfilgrastim are commercialized by our partner Teuto. The rest of the products are commercialized directly by our team.